You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVerapamil
Accession NumberDB00661  (APRD00335)
TypeSmall Molecule
GroupsApproved
DescriptionA calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]
Structure
Thumb
Synonyms
Calan
Calan sr
Covera-hs
CP-16533-1
CP-165331
D-365
Iproveratril
Isoptin
Isoptin sr
Tarka
Vérapamil
Verapamil
Verapamilo
Verapamilum
Verelan
External Identifiers
  • CP 16533-1
  • D 365
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-verapamil - 120mgTablet120 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
Alti-verapamil - 80mgTablet80 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
CalanTablet, film coated120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
CalanTablet, film coated80 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
Calan SRTablet, film coated, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-16Not applicableUs
Calan SRTablet, film coated, extended release120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1991-03-06Not applicableUs
Calan SRTablet, film coated, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1989-12-15Not applicableUs
Covera-HSTablet, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release180 mgOralPfizer Canada Inc1997-11-132013-02-15Canada
Covera-HSTablet, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release240 mgOralPfizer Canada Inc1997-11-132013-02-15Canada
Dom-verapamil SR 240mg TabletsTablet, extended release240 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Isoptin Inj 2.5mg/mlLiquid2.5 mgIntravenousAbbott Laboratories, Limited1984-12-312007-07-31Canada
Isoptin SRTablet, extended release180 mgOralBgp Pharma Ulc1994-04-21Not applicableCanada
Isoptin SRTablet, extended release120 mgOralBgp Pharma Ulc1991-12-31Not applicableCanada
Isoptin SRTablet, extended release240 mgOralBgp Pharma Ulc1988-12-31Not applicableCanada
Isoptin Tab 120mgTablet120 mgOralAbbott Laboratories, Limited1982-12-312007-07-31Canada
Isoptin Tab 80mgTablet80 mgOralAbbott Laboratories, Limited1982-12-312007-07-31Canada
Med Verapamil TabletsTablet120 mgOralMedican Pharma Incorporated1999-03-082011-03-29Canada
Med Verapamil TabletsTablet80 mgOralMedican Pharma Incorporated1999-03-082011-03-29Canada
Mylan-verapamilTablet80 mgOralMylan Pharmaceuticals Ulc1998-05-25Not applicableCanada
Mylan-verapamilTablet120 mgOralMylan Pharmaceuticals Ulc1998-05-11Not applicableCanada
Mylan-verapamil SRTablet, extended release240 mgOralMylan Pharmaceuticals Ulc2016-09-01Not applicableCanada
Mylan-verapamil SRTablet, extended release120 mgOralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada
Mylan-verapamil SRTablet, extended release240 mgOralMylan Pharmaceuticals Ulc1996-12-312016-09-01Canada
Mylan-verapamil SRTablet, extended release180 mgOralMylan Pharmaceuticals Ulc2016-06-29Not applicableCanada
Mylan-verapamil SRTablet, extended release180 mgOralMylan Pharmaceuticals Ulc1996-12-312016-06-29Canada
Mylan-verapamil SRTablet, extended release120 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Novo-veramilTablet80 mgOralTeva Canada Limited1989-12-31Not applicableCanada
Novo-veramilTablet120 mgOralTeva Canada Limited1989-12-31Not applicableCanada
Novo-veramil SRTablet, extended release240 mgOralTeva Canada Limited1996-12-31Not applicableCanada
Nu-verap SRTablet, extended release120 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-verap SRTablet, extended release180 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-verap SRTablet, extended release240 mgOralNu Pharm Inc2004-07-192012-09-04Canada
Nu-verap Tab 120mgTablet120 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-verap Tab 80mgTablet80 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Penta-verapamil - 120mgTablet120 mgOralPentapharm Ltd.1997-06-252004-07-30Canada
Penta-verapamil - 80mgTablet80 mgOralPentapharm Ltd.1997-06-252004-07-30Canada
PHL-verapamil SRTablet, extended release240 mgOralPharmel Inc2002-05-31Not applicableCanada
PMS-verapamil SRTablet, extended release240 mgOralPharmascience Inc1999-09-01Not applicableCanada
Pro-verapamil SRTablet, extended release240 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-verapamil SRTablet, extended release120 mgOralPro Doc Limitee2009-06-15Not applicableCanada
Pro-verapamil SRTablet, extended release180 mgOralPro Doc Limitee2009-06-15Not applicableCanada
Riva-verapamil SRTablet, extended release240 mgOralLaboratoire Riva Inc2005-09-14Not applicableCanada
Taro-verapamil Tab 120mgTablet120 mgOralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Taro-verapamil Tab 80mgTablet80 mgOralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Verapamil HydrochlorideCapsule, delayed release pellets120 mg/1OralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets360 mg/1Oralbryant ranch prepack1990-05-29Not applicableUs
Verapamil HydrochlorideInjection2.5 mg/mLIntravenousExela Pharma Sciences, LLC2016-04-22Not applicableUs
Verapamil HydrochlorideCapsule, extended release100 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets180 mg/1OralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets120 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-242016-10-13Us
Verapamil HydrochlorideCapsule, extended release200 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets240 mg/1OralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets180 mg/1OralCarilion Materials Management1990-05-29Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets360 mg/1OralPhysicians Total Care, Inc.2009-02-12Not applicableUs
Verapamil HydrochlorideCapsule, extended release300 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil HydrochlorideCapsule, delayed release pellets360 mg/1OralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochloride Injection 2.5mg/mlSolution2.5 mgIntravenousHospira Healthcare Corporation1994-12-31Not applicableCanada
Verapamil Hydrochloride Injection USPLiquid2.5 mgIntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Verapamil Injection 2.5mg/mlLiquid2.5 mgIntravenousNovopharm Limited1994-12-312005-08-10Canada
Verapamil SRTablet, extended release240 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
Verapamil Tab 80mgTablet80 mgOralPro Doc Limitee1990-12-312012-07-23Canada
Verapamil-120 TabTablet120 mgOralPro Doc Limitee1990-12-312009-07-23Canada
VerelanCapsule, delayed release pellets240 mg/1OralPhysicians Total Care, Inc.2004-08-12Not applicableUs
VerelanCapsule, extended release180 mgOralRecro Gainesville Llc1994-12-31Not applicableCanada
VerelanCapsule, delayed release pellets240 mg/1OralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
VerelanCapsule, delayed release pellets240 mg/1OralUCB, Inc.1990-05-292016-10-26Us
VerelanCapsule, delayed release pellets360 mg/1OralPhysicians Total Care, Inc.2003-06-12Not applicableUs
VerelanCapsule, extended release120 mgOralRecro Gainesville Llc1994-12-31Not applicableCanada
VerelanCapsule, delayed release pellets360 mg/1OralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
VerelanCapsule, delayed release pellets360 mg/1OralUCB, Inc.1990-05-292016-10-26Us
VerelanCapsule, delayed release pellets120 mg/1OralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
VerelanCapsule, delayed release pellets180 mg/1OralUCB, Inc.1990-05-292016-10-26Us
VerelanCapsule, delayed release pellets180 mg/1OralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
VerelanCapsule, delayed release pellets120 mg/1OralUCB, Inc.1990-05-292016-10-26Us
VerelanCapsule, extended release240 mgOralRecro Gainesville Llc1994-12-31Not applicableCanada
Verelan PMCapsule, extended release200 mg/1OralUCB, Inc.1998-11-252016-10-26Us
Verelan PMCapsule, extended release200 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verelan PMCapsule, extended release300 mg/1OralUCB, Inc.1998-11-252016-10-26Us
Verelan PMCapsule, extended release300 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verelan PMCapsule, extended release100 mg/1OralUCB, Inc.1998-11-252016-10-26Us
Verelan PMCapsule, extended release300 mg/1Oralbryant ranch prepack1998-11-25Not applicableUs
Verelan PMCapsule, extended release100 mg/1OralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-verap SRTablet, extended release240 mgOralApotex Inc2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release120 mgOralApotex Inc2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release180 mgOralApotex Inc2003-04-24Not applicableCanada
Apo-verap Tab 80mgTablet80 mgOralApotex Inc1989-12-31Not applicableCanada
Apo-verap Tablet 120mgTablet120 mgOralApotex Inc1989-12-31Not applicableCanada
VerapamilTablet, film coated, extended release240 mg/1OralApotex Corp.2012-11-192016-12-31Us
VerapamilTablet, film coated, extended release180 mg/1OralAmerican Health Packaging2014-01-142015-12-31Us
VerapamilTablet, film coated, extended release120 mg/1OralAmerican Health Packaging2014-01-142016-03-31Us
VerapamilTablet, film coated, extended release240 mg/1OralAmerican Health Packaging2014-01-142016-04-30Us
VerapamilTablet, film coated, extended release180 mg/1OralSt Marys Medical Park Pharmacy2013-02-05Not applicableUs
VerapamilTablet, film coated, extended release120 mg/1OralApotex Corp.2012-11-192016-12-31Us
VerapamilTablet, extended release180 mg/1OralPd Rx Pharmaceuticals, Inc.2011-08-05Not applicableUs
VerapamilTablet, film coated, extended release180 mg/1OralUnit Dose Services2012-11-19Not applicableUs
VerapamilTablet, film coated, extended release120 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
VerapamilTablet, film coated, extended release180 mg/1OralApotex Corp.2012-11-192016-12-31Us
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousHospira, Inc.1987-05-06Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralMylan Institutional Inc.1998-11-15Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralPhysicians Total Care, Inc.1996-02-05Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralPd Rx Pharmaceuticals, Inc.2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1Oralbryant ranch prepack1997-10-10Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralMylan Pharmaceuticals Inc.2009-12-28Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralA S Medication Solutions2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralNu Care Pharmaceuticals, Inc.2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralTeva Pharmaceuticals USA Inc2014-03-10Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralBlenheim Pharmacal, Inc.2011-02-15Not applicableUs
Verapamil HydrochlorideTablet80 mg/1OralREMEDYREPACK INC.2011-11-162016-11-02Us
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralCardinal Health2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralClinical Solutions Wholesale1986-10-01Not applicableUs
Verapamil HydrochlorideCapsule, extended release120 mg/1OralREMEDYREPACK INC.2010-11-222016-10-13Us
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralREMEDYREPACK INC.2013-05-14Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralClinical Solutions Wholesale2011-08-05Not applicableUs
Verapamil HydrochlorideTablet40 mg/1OralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralA S Medication Solutions2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralREMEDYREPACK INC.2011-07-212017-11-09Us
Verapamil HydrochlorideTablet, film coated80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralRebel Distributors Corp1996-02-05Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralUnit Dose Services2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousCardinal Health2011-03-25Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1Oralbryant ranch prepack1992-08-01Not applicableUs
Verapamil HydrochlorideTablet, film coated40 mg/1OralActavis Pharma, Inc.1993-06-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralPreferred Pharmaceuticals, Inc.2012-06-04Not applicableUs
Verapamil HydrochlorideCapsule, extended release180 mg/1OralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralA S Medication Solutions2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralMylan Pharmaceuticals Inc.1996-03-25Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousHospira, Inc.1998-10-20Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/1OralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/301OralNorthwind Pharmaceuticals2014-05-27Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralPhysicians Total Care, Inc.2000-05-09Not applicableUs
Verapamil HydrochlorideTablet, extended release120 mg/1OralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralMylan Pharmaceuticals Inc.1989-02-15Not applicableUs
Verapamil HydrochlorideTablet, film coated40 mg/1OralClinical Solutions Wholesale1993-06-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralPreferred Pharmaceuticals Inc.2016-11-21Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralTeva Pharmaceuticals USA Inc2014-01-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralBlenheim Pharmacal, Inc.2010-08-20Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousCardinal Health2011-03-25Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralREMEDYREPACK INC.2011-07-252016-11-02Us
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralREMEDYREPACK INC.2013-05-15Not applicableUs
Verapamil HydrochlorideCapsule, extended release300 mg/1OralPhysicians Total Care, Inc.2007-12-20Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralClinical Solutions Wholesale2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralUnit Dose Services2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralREMEDYREPACK INC.2016-07-12Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralNu Care Pharmaceuticals, Inc.2011-01-07Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralRebel Distributors Corp2010-04-20Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralMylan Institutional Inc.1996-04-15Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralA S Medication Solutions Llc1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1Oralbryant ranch prepack2010-04-20Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-01-01Not applicableUs
Verapamil HydrochlorideCapsule, extended release240 mg/1OralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil HydrochlorideTablet80 mg/1OralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralA S Medication Solutions2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralMylan Pharmaceuticals Inc.1997-02-25Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-09-22Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralREMEDYREPACK INC.2013-03-14Not applicableUs
Verapamil HydrochlorideCapsule, extended release100 mg/1OralPhysicians Total Care, Inc.2008-08-07Not applicableUs
Verapamil HydrochlorideTablet, extended release180 mg/1OralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralCardinal Health2012-07-12Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralActavis Pharma, Inc.1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralClinical Solutions Wholesale1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralLake Erie Medical DBA Quality Care Products LLC1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralTeva Pharmaceuticals USA Inc2014-04-07Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralBlenheim Pharmacal, Inc.2013-12-17Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralA S Medication Solutions Llc2011-01-07Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralMajor Pharmaceuticals1986-10-01Not applicableUs
Verapamil HydrochlorideTablet80 mg/1OralREMEDYREPACK INC.2011-08-082016-11-04Us
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Verapamil HydrochlorideCapsule, extended release200 mg/1OralPhysicians Total Care, Inc.2010-05-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil HydrochlorideCapsule, extended release120 mg/1OralMylan Institutional Inc.1999-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralPreferred Pharmaceuticals Inc.2016-05-04Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousHospira, Inc.1987-05-06Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralREMEDYREPACK INC.2011-12-132016-10-26Us
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralMylan Institutional Inc.1998-04-17Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralPhysicians Total Care, Inc.1995-04-24Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1Oralbryant ranch prepack1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralA S Medication Solutions2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/1OralA S Medication Solutions2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralNu Care Pharmaceuticals, Inc.2014-01-29Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralPhysicians Total Care, Inc.1996-01-15Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/1OralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil HydrochlorideTablet, film coated40 mg/1OralCarilion Materials Management1993-06-29Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralA S Medication Solutions2009-09-17Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralMylan Pharmaceuticals Inc.1997-09-22Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release240 mg/1OralAphena Pharma Solutions Tennessee, Llc1996-03-25Not applicableUs
Verapamil HydrochlorideTablet240 mg/1OralREMEDYREPACK INC.2012-10-022016-10-13Us
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousCardinal Health2011-03-25Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralActavis Pharma, Inc.1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/1OralPreferred Pharmaceuticals, Inc.2013-09-26Not applicableUs
Verapamil HydrochlorideCapsule, extended release120 mg/1OralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-08-05Not applicableUs
Verapamil HydrochlorideTablet80 mg/1OralRebel Distributors Corp1995-04-24Not applicableUs
Verapamil HydrochlorideTablet, film coated120 mg/1OralMajor Pharmaceuticals1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, extended release240 mg/1OralREMEDYREPACK INC.2011-12-07Not applicableUs
Verapamil HydrochlorideInjection, solution2.5 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Verapamil HydrochlorideTablet, film coated80 mg/1OralCardinal Health1986-10-01Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release180 mg/1OralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil HydrochlorideTablet120 mg/1OralREMEDYREPACK INC.2014-06-27Not applicableUs
Verapamil HydrochlorideTablet, film coated, extended release120 mg/1OralPreferred Pharmaceuticals Inc.2016-10-17Not applicableUs
Verapamil Hydrochloride PMCapsule, extended release200 mg/1OralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Verapamil Hydrochloride PMCapsule, extended release100 mg/1OralAvera Mc Kennan Hospital2015-06-25Not applicableUs
Verapamil Hydrochloride PMCapsule, extended release300 mg/1OralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Verapamil Hydrochloride PMCapsule, extended release100 mg/1OralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BosoptinBosnalijek
IsoptinAbbott
VerisopGerard
VerminRatiopharm
VerminePharmasant
VerogalidIvax
Verogalid ERIvax
VerpamilMylan
VertabTrinity-Chiesi
VetrimilCCPC
ZolveraRosemont
Brand mixtures
NameLabellerIngredients
TarkaPhysicians Total Care, Inc.
Trandolapril and Verapamil HydrochlorideGlenmark Pharmaceuticals Inc., Usa
Trandolapril and Verapamil Hydrochloride ERGreenstone LLC
Salts
Name/CASStructureProperties
Verapamil Hydrochloride
152-11-4
Thumb
  • InChI Key: DOQPXTMNIUCOSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 490.259835453
  • Average Mass: 491.063
DBSALT000534
Categories
UNIICJ0O37KU29
CAS number52-53-9
WeightAverage: 454.6016
Monoisotopic: 454.283157714
Chemical FormulaC27H38N2O4
InChI KeySGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
Pharmacology
IndicationFor the treatment of hypertension, angina, and cluster headache prophylaxis.
Structured Indications
PharmacodynamicsVerapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Mechanism of actionVerapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1FProteinyes
inhibitor
HumanO60840 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Voltage-dependent L-type calcium channel subunit beta-1Proteinyes
inhibitor
HumanQ02641 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit beta-3Proteinyes
inhibitor
HumanP54284 details
Voltage-dependent L-type calcium channel subunit beta-4Proteinyes
inhibitor
HumanO00305 details
Voltage-dependent T-type calcium channel subunit alpha-1IProteinunknown
inhibitor
HumanQ9P0X4 details
Voltage-dependent T-type calcium channel subunit alpha-1GProteinunknown
inhibitor
HumanO43497 details
Voltage-dependent N-type calcium channel subunit alpha-1BProteinunknown
inhibitor
HumanQ00975 details
Voltage-dependent P/Q-type calcium channel subunit alpha-1AProteinunknown
inhibitor
HumanO00555 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Sodium channel protein type 5 subunit alphaProteinunknown
other
HumanQ14524 details
ATP-sensitive inward rectifier potassium channel 11Proteinunknown
inhibitor
HumanQ14654 details
Sodium-dependent serotonin transporterProteinunknown
other/unknown
HumanP31645 details
Related Articles
Absorption90%
Volume of distributionNot Available
Protein binding90%
Metabolism
SubstrateEnzymesProduct
Verapamil
O-Desmethylverapamil (D-702)Details
Verapamil
Verapamil metabolite D-617Details
Verapamil
NorverapamilDetails
Verapamil
O-Desmethylverapamil (D-703)Details
O-Desmethylverapamil (D-702)
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Not Available
Verapamil metabolite PR-25Details
Norverapamil
Verapamil metabolite D-715 (PR-22)Details
Norverapamil
Verapamil metabolite D-620Details
Route of eliminationApproximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
Half life2.8-7.4 hours
ClearanceNot Available
ToxicityLD50=8 mg/kg (i.v. in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Verapamil Action PathwayDrug actionSMP00375
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe metabolism of Verapamil can be decreased when combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Verapamil.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Verapamil.Vet Approved
3,4-DichloroisocoumarinThe metabolism of Verapamil can be decreased when combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe metabolism of Verapamil can be decreased when combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Verapamil can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Verapamil.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Verapamil.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Verapamil.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Verapamil.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Verapamil.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Verapamil.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Verapamil.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Verapamil.Experimental
AlectinibThe serum concentration of Verapamil can be increased when it is combined with Alectinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Verapamil.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Verapamil.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Verapamil.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Verapamil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Verapamil.Approved, Investigational
AlogliptinThe metabolism of Verapamil can be decreased when combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Verapamil.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe metabolism of Verapamil can be decreased when combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
AlprenololVerapamil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Verapamil can be increased when it is combined with Amantadine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Verapamil.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Verapamil.Approved
AmifostineThe risk or severity of adverse effects can be increased when Verapamil is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.Approved
Aminohippuric acidThe serum concentration of Verapamil can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Verapamil.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Verapamil.Approved
Aminosalicylic AcidVerapamil may increase the anticoagulant activities of Aminosalicylic Acid.Approved
AmiodaroneVerapamil may increase the bradycardic activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Verapamil.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Verapamil.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Verapamil.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Verapamil.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.Approved, Investigational
AmprenavirThe metabolism of Verapamil can be decreased when combined with Amprenavir.Approved
AmsacrineThe serum concentration of Verapamil can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Verapamil is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Verapamil.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Verapamil.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Verapamil.Approved
Antithrombin III humanThe metabolism of Verapamil can be decreased when combined with Antithrombin III human.Approved
AnvirzelVerapamil may increase the atrioventricular blocking (AV block) activities of Anvirzel.Investigational
Aop200704Verapamil may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Verapamil.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Verapamil is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Verapamil.Approved, Investigational
AprepitantThe serum concentration of Verapamil can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe metabolism of Verapamil can be decreased when combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe metabolism of Verapamil can be decreased when combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved, Investigational
ArmodafinilThe metabolism of Verapamil can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Verapamil is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Verapamil.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Verapamil.Approved, Withdrawn
AsunaprevirThe metabolism of Verapamil can be decreased when combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Verapamil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Verapamil.Approved
AtomoxetineThe metabolism of Verapamil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Verapamil can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Verapamil is combined with Atosiban.Approved
Atracurium besylateVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Verapamil.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Verapamil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Verapamil.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Verapamil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Verapamil.Experimental
BalsalazideVerapamil may increase the anticoagulant activities of Balsalazide.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Verapamil.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Verapamil.Experimental
BarbitalBarbital may increase the hypotensive activities of Verapamil.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Barnidipine.Approved
BatimastatThe metabolism of Verapamil can be decreased when combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Verapamil.Approved
BefunololVerapamil may increase the hypotensive activities of Befunolol.Experimental
BenazeprilThe metabolism of Verapamil can be decreased when combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.Approved
BenzamidineThe metabolism of Verapamil can be decreased when combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Verapamil can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Verapamil.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Verapamil.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Verapamil.Approved
BepridilThe serum concentration of Verapamil can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantVerapamil may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Verapamil.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.Approved
BevantololVerapamil may increase the hypotensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Verapamil can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Verapamil.Approved
Bi201335The metabolism of Verapamil can be decreased when combined with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Verapamil.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Verapamil.Approved
BiperidenThe serum concentration of Verapamil can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.Approved
BivalirudinThe metabolism of Verapamil can be decreased when combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Verapamil can be decreased when combined with Boceprevir.Approved
BopindololVerapamil may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Verapamil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Verapamil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Verapamil.Approved
BretyliumBretylium may increase the bradycardic activities of Verapamil.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Verapamil.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Verapamil.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Verapamil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Verapamil.Approved
BucindololVerapamil may increase the hypotensive activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Verapamil.Approved
BufuralolVerapamil may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Verapamil.Approved, Investigational
BupranololVerapamil may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Verapamil.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Verapamil.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Verapamil.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Verapamil.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Verapamil.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Verapamil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Verapamil.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Verapamil.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Verapamil.Approved, Nutraceutical
CalciumThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CalfactantVerapamil may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Verapamil.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Verapamil.Withdrawn
CandoxatrilThe metabolism of Verapamil can be decreased when combined with Candoxatril.Experimental
CandoxatrilatThe metabolism of Verapamil can be decreased when combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Verapamil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Verapamil can be decreased when combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Verapamil is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.Approved
CarbomycinThe metabolism of Verapamil can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Verapamil.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Verapamil.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Verapamil.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Verapamil.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Verapamil.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Verapamil.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Verapamil.Approved, Vet Approved
CeritinibVerapamil may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Verapamil.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Verapamil.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Verapamil.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.Approved
ChloramphenicolThe metabolism of Verapamil can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Verapamil.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Verapamil.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Verapamil.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Verapamil.Approved, Vet Approved
ChlorpropamideThe serum concentration of Verapamil can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
CholesterolThe serum concentration of Verapamil can be increased when it is combined with Cholesterol.Experimental
Cholic AcidVerapamil may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
ChymostatinThe metabolism of Verapamil can be decreased when combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Verapamil.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Verapamil.Approved, Investigational
CilastatinThe metabolism of Verapamil can be decreased when combined with Cilastatin.Approved
CilazaprilThe metabolism of Verapamil can be decreased when combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Verapamil.Approved
CimetidineThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Verapamil.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Verapamil.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Verapamil.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Verapamil.Approved
ClarithromycinThe metabolism of Verapamil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Verapamil can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Verapamil.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Verapamil.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Verapamil is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Verapamil.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Verapamil.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Verapamil.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Verapamil.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Verapamil.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Verapamil.Approved, Illicit
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Verapamil.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Verapamil.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Verapamil.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Verapamil.Approved
CobicistatThe metabolism of Verapamil can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Verapamil.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Verapamil.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Verapamil.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Verapamil.Approved
ColforsinThe serum concentration of Verapamil can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Verapamil can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Verapamil.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Verapamil.Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.Approved
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Verapamil.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Verapamil.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Verapamil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Verapamil.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Verapamil.Approved
DabrafenibThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Verapamil.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Verapamil.Approved
DantroleneDantrolene may increase the hyperkalemic activities of Verapamil.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Verapamil.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Verapamil.Approved, Investigational
DarunavirThe metabolism of Verapamil can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Verapamil.Approved
DasatinibThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Verapamil.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Verapamil.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Verapamil.Experimental
DeferasiroxThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Verapamil can be decreased when combined with Delavirdine.Approved
dersalazineVerapamil may increase the anticoagulant activities of dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Verapamil is combined with Desflurane.Approved
DesipramineThe serum concentration of Verapamil can be increased when it is combined with Desipramine.Approved
DeslanosideVerapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DesloratadineThe serum concentration of Verapamil can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved
DexamethasoneThe serum concentration of Verapamil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Verapamil.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Verapamil.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Verapamil.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Verapamil.Approved
DiflunisalVerapamil may increase the anticoagulant activities of Diflunisal.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Verapamil.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Verapamil.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.Approved, Illicit
DihydroergotamineThe metabolism of Verapamil can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Verapamil.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Verapamil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.Approved
DisopyramideThe risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Verapamil.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Verapamil.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Verapamil.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Verapamil.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Verapamil.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Verapamil.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Verapamil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Verapamil.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Verapamil.Approved, Investigational
DoxycyclineThe metabolism of Verapamil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Verapamil.Approved, Illicit
DronedaroneVerapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
DuloxetineVerapamil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Verapamil.Approved, Investigational
EcabetThe metabolism of Verapamil can be decreased when combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Verapamil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.Approved
EfavirenzThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Verapamil.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Efonidipine.Approved
ElafinThe metabolism of Verapamil can be decreased when combined with Elafin.Investigational
ElbasvirThe serum concentration of Verapamil can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Verapamil.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Verapamil.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Verapamil.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.Approved
EnalaprilThe metabolism of Verapamil can be decreased when combined with Enalapril.Approved, Vet Approved
EnalaprilatThe metabolism of Verapamil can be decreased when combined with Enalaprilat.Approved
EnalkirenThe metabolism of Verapamil can be decreased when combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Verapamil.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Verapamil.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Verapamil is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Verapamil.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Verapamil.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Verapamil.Approved, Investigational
ErythromycinThe metabolism of Verapamil can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Verapamil.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Verapamil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Verapamil.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Verapamil.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Verapamil.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Verapamil.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Verapamil.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Verapamil.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Verapamil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Verapamil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Verapamil.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Verapamil.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Verapamil.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Verapamil.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Verapamil.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Verapamil.Approved, Investigational
EtravirineThe serum concentration of Verapamil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Verapamil.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Verapamil.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Verapamil.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Verapamil.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Verapamil.Approved
FelodipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Verapamil.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Verapamil is combined with Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.Approved
FexofenadineThe bioavailability of Fexofenadine can be increased when combined with Verapamil.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Verapamil.Approved
FimasartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Verapamil.Approved
FingolimodVerapamil may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideThe risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Verapamil.Approved
FloxuridineThe metabolism of Verapamil can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Verapamil can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Verapamil.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Verapamil.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Verapamil.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Verapamil.Approved
FluorouracilThe metabolism of Verapamil can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Verapamil.Approved, Vet Approved
FlupentixolThe serum concentration of Verapamil can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Verapamil can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Verapamil.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Verapamil.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Verapamil.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Verapamil.Approved
FluvoxamineThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Verapamil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe metabolism of Verapamil can be decreased when combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Verapamil.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.Approved
GabexateThe metabolism of Verapamil can be decreased when combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Verapamil.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Verapamil.Approved, Investigational
GeldanamycinThe metabolism of Verapamil can be decreased when combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Verapamil.Approved
GemfibrozilThe metabolism of Verapamil can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Verapamil can be increased when it is combined with Genistein.Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Verapamil.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Verapamil.Approved
GlycerolThe serum concentration of Verapamil can be increased when it is combined with Glycerol.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Verapamil.Experimental
GM6001The metabolism of Verapamil can be decreased when combined with GM6001.Experimental
Gramicidin DThe serum concentration of Verapamil can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Verapamil.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Verapamil.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Verapamil.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Verapamil.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Verapamil is combined with Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Verapamil.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Verapamil.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Verapamil.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Verapamil.Approved, Vet Approved
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Verapamil.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Verapamil.Approved
HirulogThe metabolism of Verapamil can be decreased when combined with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Verapamil.Approved
HydralazineThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Verapamil.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Verapamil.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Verapamil.Approved
IdelalisibThe serum concentration of Verapamil can be increased when it is combined with Idelalisib.Approved
idraparinuxThe metabolism of Verapamil can be decreased when combined with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Verapamil.Approved
IloprostThe risk or severity of adverse effects can be increased when Verapamil is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Verapamil.Approved
ImidaprilThe metabolism of Verapamil can be decreased when combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Verapamil.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Verapamil.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Verapamil.Approved
IndapamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.Approved
IndenololVerapamil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Verapamil can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Verapamil.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Verapamil.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Verapamil.Approved, Investigational
IsavuconazoniumThe metabolism of Verapamil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Verapamil is combined with Isocarboxazid.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Verapamil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Verapamil is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe metabolism of Verapamil can be decreased when combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Verapamil can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Verapamil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Verapamil.Approved
ItraconazoleThe metabolism of Verapamil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Verapamil.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Verapamil.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Verapamil.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Verapamil.Approved, Investigational
IxazomibThe metabolism of Verapamil can be decreased when combined with Ixazomib.Approved
JosamycinThe metabolism of Verapamil can be decreased when combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Verapamil.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Verapamil.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Verapamil.Approved
KetoconazoleThe metabolism of Verapamil can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Verapamil can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Verapamil.Approved
LacidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Lacidipine.Approved
LacosamideVerapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Verapamil.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Verapamil.Approved, Investigational
LanreotideVerapamil may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Verapamil.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Verapamil.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Verapamil.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Verapamil.Approved
LeflunomideThe metabolism of Verapamil can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Verapamil.Approved
LepirudinThe metabolism of Verapamil can be decreased when combined with Lepirudin.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Verapamil.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Verapamil.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Verapamil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Verapamil is combined with Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Verapamil.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Verapamil.Approved
LevodopaVerapamil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Verapamil.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Verapamil.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Verapamil is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Verapamil.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Verapamil.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Verapamil.Approved
LiothyronineThe serum concentration of Verapamil can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Verapamil can be decreased when it is combined with Liotrix.Approved
LisinoprilThe metabolism of Verapamil can be decreased when combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Verapamil.Approved
LithiumVerapamil may increase the neurotoxic activities of Lithium.Approved
LofexidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Verapamil.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Verapamil.Approved
LopinavirThe metabolism of Verapamil can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Verapamil.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Verapamil.Approved
LosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Verapamil.Approved, Investigational
LucinactantVerapamil may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Verapamil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Verapamil can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Verapamil.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Verapamil.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Verapamil can be increased when it is combined with Maprotiline.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Verapamil.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Verapamil.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Verapamil.Approved
Megestrol acetateThe serum concentration of Verapamil can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Verapamil.Approved, Vet Approved
MeprobamateThe serum concentration of Verapamil can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineVerapamil may increase the anticoagulant activities of Mesalazine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Verapamil.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Verapamil.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Verapamil.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Verapamil.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Verapamil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Verapamil.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Verapamil.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Verapamil.Approved
MetipranololThe risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Verapamil.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Verapamil.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Verapamil.Experimental
MexiletineThe metabolism of Verapamil can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Verapamil.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Verapamil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Verapamil.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Verapamil.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Verapamil.Approved, Illicit
MidodrineVerapamil may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Verapamil.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Verapamil.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Verapamil.Approved
MitomycinThe serum concentration of Verapamil can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Verapamil can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Verapamil.Approved, Investigational
MivacuriumVerapamil may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideThe metabolism of Verapamil can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Verapamil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe metabolism of Verapamil can be decreased when combined with Moexipril.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Verapamil.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Verapamil.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Verapamil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Verapamil.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe metabolism of Verapamil can be decreased when combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Verapamil is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.Approved
NafamostatThe metabolism of Verapamil can be decreased when combined with Nafamostat.Investigational
NafcillinThe metabolism of Verapamil can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Verapamil.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Verapamil.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Verapamil.Approved, Vet Approved
NaltrexoneThe serum concentration of Verapamil can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Verapamil can be increased when it is combined with Naringenin.Experimental
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Verapamil.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Verapamil.Approved, Investigational
NCX 4016The metabolism of Verapamil can be decreased when combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Verapamil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Verapamil can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Verapamil can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Verapamil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Verapamil can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Verapamil can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Verapamil.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Verapamil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Nifedipine.Approved
NilotinibThe metabolism of Nilotinib can be decreased when combined with Verapamil.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Verapamil.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Verapamil.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Verapamil.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Verapamil.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Verapamil.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitric Oxide.Approved
NitroaspirinThe metabolism of Verapamil can be decreased when combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.Approved, Investigational
NitroprussideVerapamil may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Verapamil.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Verapamil.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Verapamil.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Verapamil.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Verapamil.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Verapamil.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Verapamil is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the bradycardic activities of Verapamil.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Verapamil.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Verapamil.Approved
OleandomycinThe metabolism of Verapamil can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.Approved, Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
OlsalazineVerapamil may increase the anticoagulant activities of Olsalazine.Approved
OmapatrilatThe metabolism of Verapamil can be decreased when combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Verapamil.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Verapamil.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Verapamil.Approved
OsimertinibThe serum concentration of Verapamil can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Verapamil.Approved
OtamixabanThe metabolism of Verapamil can be decreased when combined with Otamixaban.Investigational
OuabainVerapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Verapamil.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Verapamil.Approved
OxprenololThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Verapamil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Verapamil can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Verapamil.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Verapamil.Investigational
PalbociclibThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Verapamil can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Verapamil.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Verapamil.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Verapamil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Verapamil.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Verapamil.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Verapamil.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Verapamil.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Verapamil.Approved
ParoxetineThe serum concentration of Verapamil can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideVerapamil may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.Approved
Peginterferon alfa-2bThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Verapamil is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Verapamil.Approved
PentobarbitalThe metabolism of Verapamil can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Verapamil.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Verapamil.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Verapamil.Approved
PerindoprilThe metabolism of Verapamil can be decreased when combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Verapamil.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Verapamil.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Verapamil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Verapamil.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Verapamil is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Verapamil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Verapamil.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Verapamil.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Verapamil is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Verapamil.Approved, Vet Approved
PhosphoramidonThe metabolism of Verapamil can be decreased when combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Verapamil.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Verapamil.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Verapamil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Verapamil.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Verapamil.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Verapamil.Approved
Platelet Activating FactorThe serum concentration of Verapamil can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Verapamil.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Verapamil.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Verapamil.Approved
Poractant alfaVerapamil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Verapamil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololVerapamil may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Verapamil is combined with Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Verapamil.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Verapamil.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Verapamil.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Verapamil.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Verapamil.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Verapamil.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Verapamil.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Verapamil.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Verapamil.Approved
PrimidoneThe metabolism of Verapamil can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe metabolism of Verapamil can be decreased when combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Verapamil can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Verapamil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Verapamil.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Verapamil.Approved, Vet Approved
PromethazineThe serum concentration of Verapamil can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Verapamil.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.Approved, Investigational
ProtriptylineThe serum concentration of Verapamil can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Verapamil.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Verapamil.Approved
PyrimethamineThe metabolism of Verapamil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Verapamil can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Verapamil can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Verapamil.Approved
QuinaprilThe metabolism of Verapamil can be decreased when combined with Quinapril.Approved, Investigational
QuinidineQuinidine may increase the hypotensive activities of Verapamil.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Verapamil.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Verapamil.Approved, Investigational
RacecadotrilThe metabolism of Verapamil can be decreased when combined with Racecadotril.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Verapamil.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Verapamil.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Verapamil.Approved, Investigational
RamiprilThe metabolism of Verapamil can be decreased when combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Verapamil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Verapamil.Approved, Investigational
RapacuroniumVerapamil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Verapamil is combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Verapamil.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Verapamil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Verapamil is combined with Remifentanil.Approved
RemikirenThe metabolism of Verapamil can be decreased when combined with Remikiren.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Verapamil.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Verapamil.Approved
RifabutinThe metabolism of Verapamil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Verapamil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Verapamil can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Verapamil.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Verapamil.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Verapamil is combined with Riociguat.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Verapamil.Approved, Investigational
RitonavirThe metabolism of Verapamil can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Verapamil can be decreased when combined with Rivaroxaban.Approved
RivastigmineVerapamil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Verapamil.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Verapamil.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Verapamil.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Verapamil.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Verapamil.Approved
RosiglitazoneThe metabolism of Verapamil can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Verapamil.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Verapamil.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Verapamil.Approved, Withdrawn
RuxolitinibRuxolitinib may increase the bradycardic activities of Verapamil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Verapamil is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Verapamil.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Verapamil.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.Approved
SaquinavirThe metabolism of Verapamil can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Verapamil.Approved
ScopolamineThe serum concentration of Verapamil can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Verapamil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Verapamil.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Verapamil.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Verapamil.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Verapamil.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Verapamil.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Verapamil.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Verapamil can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Verapamil.Approved
SiltuximabThe serum concentration of Verapamil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Verapamil.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Verapamil.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Verapamil.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Verapamil.Approved, Investigational
SitagliptinThe metabolism of Verapamil can be decreased when combined with Sitagliptin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Verapamil is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Verapamil.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Verapamil.Approved
SolithromycinThe metabolism of Verapamil can be decreased when combined with Solithromycin.Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Verapamil.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Verapamil.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Verapamil.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Verapamil.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Verapamil.Approved
SpiraprilThe metabolism of Verapamil can be decreased when combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.Approved
St. John's WortThe serum concentration of Verapamil can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Verapamil can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Verapamil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Verapamil is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Verapamil can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Verapamil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Verapamil.Approved
SulfadiazineThe metabolism of Verapamil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.Approved
SulfisoxazoleThe metabolism of Verapamil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Verapamil can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Verapamil.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.Approved
TacrineThe serum concentration of Verapamil can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Verapamil.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Verapamil.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Verapamil.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Verapamil.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Verapamil.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Verapamil.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Verapamil.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Verapamil.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Verapamil.Approved
TelaprevirThe metabolism of Verapamil can be decreased when combined with Telaprevir.Approved
TelithromycinTelithromycin may increase the bradycardic activities of Verapamil.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Verapamil.Approved
TemocaprilThe metabolism of Verapamil can be decreased when combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Verapamil.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Verapamil.Approved
TenofovirThe metabolism of Verapamil can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Verapamil.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Verapamil.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Verapamil.Withdrawn
TeriflunomideThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Verapamil.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Verapamil.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Verapamil.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Verapamil is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Verapamil.Approved
ThiamylalThiamylal may increase the hypotensive activities of Verapamil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Verapamil.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.Approved
ThiorphanThe metabolism of Verapamil can be decreased when combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Verapamil.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Verapamil.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Verapamil.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Verapamil.Approved
TiclopidineThe metabolism of Verapamil can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Verapamil.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Verapamil.Approved, Investigational
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Verapamil.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Verapamil.Approved
TipranavirThe metabolism of Verapamil can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Verapamil.Approved
TocilizumabThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Verapamil.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Verapamil is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Verapamil can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Verapamil is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Verapamil.Approved, Vet Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Verapamil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Verapamil.Approved
TopiramateThe metabolism of Verapamil can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Verapamil.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Verapamil.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Verapamil.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Verapamil.Approved, Investigational
TrandolaprilThe metabolism of Verapamil can be decreased when combined with Trandolapril.Approved
TranylcypromineThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Verapamil.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Verapamil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Verapamil.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Verapamil.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Verapamil.Approved
TrifluoperazineThe serum concentration of Verapamil can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Verapamil can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Verapamil.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Verapamil.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Verapamil.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Verapamil.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Verapamil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Verapamil.Withdrawn
TroleandomycinThe metabolism of Verapamil can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Verapamil can be decreased when combined with Tylosin.Vet Approved
UbenimexThe metabolism of Verapamil can be decreased when combined with Ubenimex.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Verapamil.Approved, Investigational
UlinastatinThe metabolism of Verapamil can be decreased when combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Verapamil.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Verapamil.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Verapamil.Investigational, Withdrawn
Valproic AcidThe metabolism of Verapamil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Verapamil.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Verapamil.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Verapamil.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Verapamil.Approved
VemurafenibThe serum concentration of Verapamil can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Verapamil.Approved
VenlafaxineThe metabolism of Verapamil can be decreased when combined with Venlafaxine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Verapamil.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Verapamil.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.Approved
VildagliptinThe metabolism of Verapamil can be decreased when combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Verapamil.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Verapamil.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Verapamil.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Verapamil.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Verapamil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Verapamil.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Verapamil.Approved
XimelagatranThe metabolism of Verapamil can be decreased when combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The metabolism of Verapamil can be decreased when combined with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Verapamil.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Verapamil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Verapamil.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Verapamil.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Verapamil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Verapamil can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Verapamil can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Verapamil.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Verapamil.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Verapamil.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Verapamil.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid natural licorice.
  • Avoid taking with grapefruit juice.
  • Take with food.
References
Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, “Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms.” U.S. Patent US4859469, issued April, 1987.

US4859469
General References
  1. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386 ]
External Links
ATC CodesC08DA51C08DA01C09BB10
AHFS Codes
  • 24:28.92
PDB EntriesNot Available
FDA labelDownload (1.9 MB)
MSDSDownload (73.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9371
Blood Brain Barrier+0.6323
Caco-2 permeable+0.738
P-glycoprotein substrateSubstrate0.7874
P-glycoprotein inhibitor IInhibitor0.9056
P-glycoprotein inhibitor IIInhibitor0.855
Renal organic cation transporterInhibitor0.6259
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8706
CYP450 3A4 substrateSubstrate0.7657
CYP450 1A2 substrateNon-inhibitor0.9553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9181
Ames testNon AMES toxic0.8393
CarcinogenicityNon-carcinogens0.6463
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4137 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7687
hERG inhibition (predictor II)Inhibitor0.8188
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mylan pharmaceuticals inc
  • Elan drug delivery inc
  • Gd searle llc
  • Fsc laboratories inc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Ranbaxy laboratories inc
  • Glenmark generics ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Pliva inc
  • Actavis elizabeth llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral180 mg
TabletOral80 mg
Tablet, extended releaseOral180 mg/1
Tablet, extended releaseOral240 mg/1
TabletOral120 mg
Tablet, extended releaseOral120 mg
Tablet, extended releaseOral240 mg
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral180 mg/1
Capsule, extended releaseOral240 mg/1
InjectionIntravenous2.5 mg/mL
Injection, solutionIntravenous2.5 mg/mL
TabletOral120 mg/1
TabletOral240 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral240 mg/301
Tablet, film coatedOral120 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Tablet, film coated, extended releaseOral120 mg/1
Tablet, film coated, extended releaseOral180 mg/1
Tablet, film coated, extended releaseOral240 mg/1
SolutionIntravenous2.5 mg
LiquidIntravenous2.5 mg
Capsule, delayed release pelletsOral120 mg/1
Capsule, delayed release pelletsOral180 mg/1
Capsule, delayed release pelletsOral240 mg/1
Capsule, delayed release pelletsOral360 mg/1
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral180 mg
Capsule, extended releaseOral240 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Prices
Unit descriptionCostUnit
Verelan 360 mg 24 Hour Capsule6.82USD capsule
Verelan 360 mg cap pellet6.73USD pellet
Verelan pm 300 mg cap pellet5.87USD pellet
Verelan 240 mg 24 Hour Capsule4.76USD capsule
Verelan 240 mg cap pellet4.58USD pellet
Verelan 180 mg 24 Hour Capsule4.22USD capsule
Verelan 180 mg cap pellet4.06USD pellet
Verelan pm 200 mg cap pellet4.04USD pellet
Verelan 120 mg cap pellet3.87USD pellet
Verapamil HCl CR 300 mg 24 Hour Capsule3.82USD capsule
Isoptin sr 240 mg tablet3.32USD tablet
Verapamil hcl powder3.24USD g
Calan SR 240 mg Controlled Release Tabs3.15USD tab
Isoptin SR 240 mg Controlled Release Tabs3.14USD tab
Verelan pm 100 mg cap pellet3.13USD pellet
Calan sr 240 mg caplet3.09USD caplet
Covera-HS 240 mg 24 Hour tablet3.09USD tablet
Covera-hs 240 mg tablet sa2.97USD tablet
Isoptin sr 180 mg tablet2.9USD tablet
Calan SR 180 mg Controlled Release Tabs2.8USD tab
Isoptin SR 180 mg Controlled Release Tabs2.74USD tab
Calan sr 180 mg caplet2.7USD caplet
Verapamil HCl CR 200 mg 24 Hour Capsule2.62USD capsule
Isoptin sr 120 mg tablet2.29USD tablet
Calan SR 120 mg Controlled Release Tabs2.27USD tab
Covera-HS 180 mg 24 Hour tablet2.2USD tablet
Isoptin SR 120 mg Controlled Release Tabs2.16USD tab
Calan sr 120 mg caplet2.13USD caplet
Covera-hs 180 mg tablet sa2.11USD tablet
Verapamil HCl CR 360 mg 24 Hour Capsule2.1USD capsule
Verapamil HCl CR 100 mg 24 Hour Capsule2.04USD capsule
Isoptin Sr 240 mg Sustained-Release Tablet2.03USD tablet
Calan sr 240 mg caplet sa1.77USD caplet
Verapamil HCl CR 240 mg 24 Hour Capsule1.69USD capsule
Verapamil HCl CR 240 mg Controlled Release Tabs1.6USD tab
Calan 120 mg tablet1.56USD tablet
Isoptin Sr 180 mg Sustained-Release Tablet1.52USD tablet
Verapamil HCl CR 180 mg 24 Hour Capsule1.5USD capsule
Calan sr 180 mg caplet sa1.46USD caplet
Verapamil HCl CR 120 mg 24 Hour Capsule1.43USD capsule
Verapamil HCl CR 180 mg Controlled Release Tabs1.41USD tab
Isoptin Sr 120 mg Sustained-Release Tablet1.34USD tablet
Calan 80 mg tablet1.25USD tablet
Verapamil 2.5 mg/ml vial1.18USD ml
Verapamil HCl CR 120 mg Controlled Release Tabs1.12USD tab
Apo-Verap Sr 240 mg Sustained-Release Tablet0.91USD tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Calan 40 mg tablet0.76USD tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet0.72USD tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet0.72USD tablet
Verapamil HCl 120 mg tablet0.71USD tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet0.69USD tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet0.69USD tablet
Verapamil HCl 80 mg tablet0.56USD tablet
Apo-Verap 120 mg Tablet0.45USD tablet
Mylan-Verapamil 120 mg Tablet0.45USD tablet
Nu-Verap 120 mg Tablet0.45USD tablet
Verapamil 120 mg tablet0.39USD tablet
Verapamil 80 mg tablet0.31USD tablet
Verapamil HCl 40 mg tablet0.29USD tablet
Apo-Verap 80 mg Tablet0.29USD tablet
Mylan-Verapamil 80 mg Tablet0.29USD tablet
Nu-Verap 80 mg Tablet0.29USD tablet
Verapamil 40 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5785994 No1992-10-222009-10-22Us
US6096339 No1997-04-042017-04-04Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point243-246 °C at 1.00E-02 mm HgPhysProp
water solubility4.47 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
Caco2 permeability-4.58ADME Research, USCD
pKa8.92SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-004l-0702900000-6a46ea2d5eed6d8b01ebView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0006-4109800000-80d342090a0be3344e82View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-054w-0954400000-2def387c7c93ab211423View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-0a4i-0000900000-4cde9a4b3a4f83d16afcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-0a4i-0000900000-980b47834e505d54a0e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-066r-0902800000-ae024239c46b33917426View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-014i-0901000000-81d1159b3102cff76218View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-014i-0900000000-d9c344fee7b45b4030e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0gb9-0914000000-070bdb975910e9aae99cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-03di-0390000000-f41d80462c5d06c4f001View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0097-2980000000-9a2ab0bcab33f7eaac6bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0uxr-0900000000-252a9989a8511cb2db80View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0udi-3519000000-b5e0b9e0caac5cb57222View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Phenylpropane
  • Phenethylamine
  • Benzyl-cyanide
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Tertiary aliphatic amine
  • Tertiary amine
  • Nitrile
  • Carbonitrile
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. [PubMed:15286207 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. [PubMed:15880143 ]
  4. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-volta...
Gene Name:
CACNA1I
Uniprot ID:
Q9P0X4
Molecular Weight:
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [PubMed:16699084 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-...
Gene Name:
CACNA1B
Uniprot ID:
Q00975
Molecular Weight:
262493.84 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to...
Gene Name:
CACNA1A
Uniprot ID:
O00555
Molecular Weight:
282362.39 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [PubMed:17588331 ]
  2. Cheng HC, Incardona J, McCullough B: Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):278-87. Epub 2006 Feb 28. [PubMed:16507347 ]
  3. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. [PubMed:15814090 ]
  4. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC: Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol. 2004 May;36(5):701-5. [PubMed:15135665 ]
  5. Shimizu W, Aiba T, Antzelevitch C: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des. 2005;11(12):1561-72. [PubMed:15892662 ]
  6. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10. [PubMed:15944809 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectific...
Gene Name:
KCNJ11
Uniprot ID:
Q14654
Molecular Weight:
43540.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Yamada S, Kane GC, Behfar A, Liu XK, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A: Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006 Dec 15;577(Pt 3):1053-65. Epub 2006 Oct 12. [PubMed:17038430 ]
  3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. [PubMed:17409272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. [PubMed:2940099 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  3. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  4. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. [PubMed:10997946 ]
  5. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728 ]
  6. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  7. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  8. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  9. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  10. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67. [PubMed:12604704 ]
  11. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  12. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  13. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226 ]
  14. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
  15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724 ]
  16. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  17. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455 ]
  18. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615 ]
  19. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059 ]
  20. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004 ]
  21. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409 ]
  22. Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7. [PubMed:10075817 ]
  23. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141 ]
  24. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255 ]
  25. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025 ]
  26. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9. [PubMed:15240100 ]
  27. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
  28. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11. [PubMed:15176077 ]
  29. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. [PubMed:12569305 ]
  30. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  31. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. [PubMed:15359574 ]
  32. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  33. Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63. [PubMed:9395229 ]
  34. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078 ]
  35. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. doi: 10.1016/j.toxlet.2009.11.018. Epub 2009 Nov 26. [PubMed:19944135 ]
  36. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452 ]
  37. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
  38. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439 ]
  39. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
  40. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
  41. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  42. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. [PubMed:10773005 ]
  43. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  44. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  45. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  46. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
  47. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039 ]
  48. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  49. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  50. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927 ]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27. [PubMed:16384552 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
  2. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95. [PubMed:15155841 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:37